Results 11 to 20 of about 92,350 (272)
Tocilizumab for Treatment of Patients With Severe COVID–19: A Retrospective Cohort Study
Background: Tocilizumab was approved for chimeric antigen receptor T–cell therapy induced cytokine release syndrome and it may provide clinical benefit for selected COVID–19 patients. Methods: In this retrospective cohort study, we analyzed hypoxic COVID–
Fahrettin Covut +2 more
exaly +3 more sources
Purpose The efficacy of tocilizumab in refractory chronic noninfectious uveitis has been previously reported, but no data comparing intravenous and subcutaneous tocilizumab in uveitis are available.
Mathilde Leclercq +6 more
doaj +2 more sources
Observational Study of Tocilizumab in Children With Febrile Infection‐Related Epilepsy Syndrome
Objective This study aimed to assess the efficacy and safety of using tocilizumab in children with febrile infection‐related epilepsy syndrome (FIRES) and explore tocilizumab‐related changes in interleukin (IL)‐6 levels.
Yushan He +7 more
doaj +2 more sources
Early tocilizumab and outcomes in acute necrotizing encephalopathy
Early tocilizumab and outcome in acute necrotising encephalopathy. Aim To evaluate the timing and safety of tocilizumab in acute necrotizing encephalopathy (ANE). Method This was a multicentre retrospective study evaluating outcomes (modified Rankin Scale [mRS]) in children with ANE treated with tocilizumab. A logistic regression model determined a cut‐
Velda X Han +14 more
wiley +2 more sources
Background: Several studies have revealed the potential use of tocilizumab in treating COVID-19 since no therapy has yet been approved for COVID-19 pneumonia.
Cahyo Wibisono Nugroho +10 more
doaj +1 more source
Tocilizumab treatment in critically ill patients with COVID-19: A retrospective observational study
Objective: Elevated levels of pro-inflammatory cytokines are observed in severe COVID-19 infections, and cytokine storm is associated with disease severity.
Edmund Huang +5 more
doaj +1 more source
The quantitation of serum tocilizumab using liquid chromatography tandem-mass spectrometry (LC-MS/MS) method has not been widely applied in clinical settings because of its time-consuming and costly sample pretreatments.
Takashi Mochizuki +6 more
doaj +1 more source
Subcutaneous tocilizumab in the management of non-infectious uveitis in children: a brief report
Background Tocilizumab is a humanized monoclonal antibody that acts as an IL-6 receptor antagonist. Intravenous tocilizumab is considered an option for children with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis.
Francesca Burlo +7 more
doaj +1 more source
Therapeutic effectiveness of tocilizumab in the treatment of cytokine release syndrome in patients with COVID-19 [PDF]
Introducción: tocilizumab, fue aprobado en el 2017 por la Food and Drugs Administration para el tratamiento del síndrome de liberación de citoquinas, por lo que se ha empleado en la terapéutica de pacientes graves por SARS-CoV 2.
Denis-Piedra, Daniel Alejandro +2 more
core +1 more source

